RecruitingPhase 2NCT06084806

Test-retest Evaluation of [18F]F-AraG PET

Test-retest Evaluation of [18F]F-AraG PET in Non-small Cell Lung Cancer (NSCLC) Patients

Sponsor

CellSight Technologies, Inc.

Enrollment

10 participants

Start Date

Oct 31, 2023

Study Type

INTERVENTIONAL

Conditions

Non-small Cell Lung Cancer

Summary

This pilot study aims to evaluate the test-retest variability of \[18F\]F-AraG-PET imaging in patients with advanced NSCLC tumors. The main objectives of the study are to quantify the uptake of \[18F\]F-AraG in tumors and lymphoid tissue in two consecutive scans spaced not longer than 7 days apart from each other to estimate the magnitude of physiologic and measurement variability. To explore these objectives, eligible subjects will undergo two \[18F\]F-AraG PET/CT scans within 7 days of each other prior to receiving treatment. This study is a single-site, open-label, non-randomized, single-arm pilot trial. Patients and care providers will not be blinded to any part of the study.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests a new type of PET scan called [18F]F-AraG PET, which can visualize immune cells inside tumors. The study checks whether the scan gives consistent results when done twice in a short period, in patients with advanced lung cancer who are about to start immunotherapy. **You may be eligible if...** - You are over 18 years old - You have non-small cell lung cancer (NSCLC) confirmed by biopsy that has spread or is advanced - You are about to start immunotherapy (alone or with other treatments) - You have measurable disease on imaging - Your overall health is reasonable (ECOG 0, 1, or 2) **You may NOT be eligible if...** - You have serious coexisting health conditions that would make study participation unsafe - You are pregnant or breastfeeding - You have severe claustrophobia that prevents PET scanning Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.